Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dravet syndrome
Biotech
Biogen pays Stoke $165M, bagging Dravet drug to fire up pipeline
Biogen is paying Stoke $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying Dravet drug.
Nick Paul Taylor
Feb 18, 2025 9:28am
Encoded lays off 29% of staff to fund Dravet gene therapy trial
Feb 13, 2025 10:20am
Takeda axes epilepsy asset after FDA weighs in on data package
Jan 30, 2025 7:19am
Stoke's Dravet syndrome med released of partial clinical hold
Aug 7, 2024 8:54am
Takeda takes $140M loss on failed epilepsy drug, touts FDA run
Jul 31, 2024 9:14am
Takeda flunks pivotal epilepsy tests but mulls path to market
Jun 17, 2024 8:50am
